Pre-Made Rilonacept Biosimilar, Fusion Protein targeting IL1B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-1/IL1-BETA/IL1F2/IL1beta for drug discovery and mechanism of action (MOA) research

Pre-Made Rilonacept Biosimilar, Fusion Protein targeting IL1B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-1/IL1-BETA/IL1F2/IL1beta is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.[1][2][3] Rilonacept is an interleukin 1 inhibitor.[4]

Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1. Rilonacept is used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-973-1mg	1mg	3090
GMP-Bios-INN-973-10mg	10mg	Inquiry
GMP-Bios-INN-973-100mg	100mg	Inquiry
GMP-Bios-INN-973-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rilonacept Biosimilar, Fusion Protein targeting IL1B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IL-1/IL1-BETA/IL1F2/IL1beta
INN Name	Rilonacept
Target	IL1B
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [IL1RAP (interleukin-1 receptor accessory protein) - IL1R1 (type 1 interleukin-1 receptor, interleukin 1 receptor, type I)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [IL1RAP (interleukin-1 receptor accessory protein) - IL1R1 (type 1 interleukin-1 receptor, interleukin 1 receptor, type I)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Regeneron Pharmaceuticals Inc. (Tarrytown NY USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0